GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Jonathan D. Roth(Rutgers, The State University of New Jersey), David G. Parkes(Amplyx Pharmaceuticals (United States)), Steve Chen, Mary Erickson(Intercept Pharmaceuticals (United States))
Cited by 73
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278
NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing
|Nature Communications|2023|203